Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
TP Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced that the company raised $45 million in a Series C financing round. The round was co-led by Lilly Asia Ventures (LAV), OrbiMed Advisors, LLC, and S.R. One, Limited, and joined by existing investors Cormorant Asset Management and SV Tech Ventures. In conjunction with the financing, Carl L.
Article in Press Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib Viola W. ZhuxViola W.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
